The proto-oncogene c-erbB-2 (also known as neu or HER-2) is a 190 kilodalton transmembrane glycoprotein similar in structure to the epidermal growth factor receptor (EGFR) (Coussens et al., 1985) . The extracellular domains of the two proteins are 40% identical in sequence and both possess two regions rich in cysteine residues which may be responsible for stabilisation of their three dimensional structure and ability to bind ligands. No ligand has yet however been definitively identified for the c-erbB-2 protein although an activity present in the conditioned medium of ras transformed cells has bene reported (Yarden & Weinberg, 1989) . The two proteins are also identical in sequence in about 80% of their amino acids forming the intracellular tyrosine kinase domain.
The c-erbB-2 protein was originally identified in rats where it is generally called neu. In a transplacental chemical carcinogenesis model an activated oncogene was isolated which was later determined to be a mutated form of neu. The mutation occurred in a specific residue in the transmembrane sequence (Bargmann & Weinberg, 1989) which stabilised receptor dimerisation and activated its tyrosine kinase (Weiner et al., 1989) . A model of the three dimensional structure of this region suggests that dimerisation is stabilised by hydrogen bonding (Sternberg & Gullick, 1989) .
Monoclonal antibodies which bind to and down regulate mutant receptor expression inhibit tumour cell growth in vitro and in vivo (Maguire & Greene, 1989) . Overexpression of the normal c-erbB-2 protein in NIH 3T3 cells leads to transformation (Di Fiore et al., 1987; Hudziak et al., 1987) . The c-erbB-2 protein is overexpressed in 15-20% of human invasive cancers (Gullick & Venter, 1989) and in a high proportion of ductal carcinomas in situ of the comedo type (Van de Vijver et al., 1988 b) and in cases of Pagets disease of the nipple . Recently antibodies to natural human c-erbB-2 have been shown to inhibit the growth of the breast cancer derived cell line SKBR-3 which expresses high levels of the protein (Hudziak et al., 1989) .
There has been increasing interest in the role of c-erbB-2 oncogene in breast cancer, particularly its relationship to prognosis . Overexpression of c-erbB-2 oncogene has been shown to correlate with poor prognosis in both primary operable and advanced breast cancer patients by some groups (Varley et al., 1987; Slamon et al., 1987; Walker et al., 1989; Tsuda et al., 1989; Wright et al., 1989; Slamon et al., 1989; Tandon et al., 1989; Paik et al., 1990) but this significant association has not been demonstrated by others ; Van de Vijver et al., 1988a; Barnes et al., 1988; Gusterson et al., 1988; Ali et al., 1988; Zhou et al., 1989) and remains controversial. c-erbB-2 oncogene product can be detected immunohistologically in patients with breast cancer. Previous studies with the antibody 21N and others, using southern blotting and immunohistological staining have demonstrated that tumour cell membrane reactivity is related to c-erbB-2 gene amplification Gusterson et al., 1987) . Use of immunohistology to detect elevated levels of c-erbB-2 protein expression allows study of archival tumour samples from well characterised series. In this study we have examined, in a large series of patients managed by a single team, the prognostic effect of c-erbB-2 oncoprotein expression in primary and advanced breast carcinoma and its value in relationship to existing prognostic factors. (Elston, 1987) (Figure 3) according to c-erbB-2 statistics shows no significant difference in survival between c-erbB-2 positive and negative lymph node negative patients. Significant differences in survival were found between c-erbB-2 negative, node negative and positive patients, c-erbB-2 positive node negative and positive patients, and node positive c-erbB-2 (Cox, 1972) was used to identify whether c-erbB-2 was of independent prognostic significance. In the context of the temporal variables, tumour size and lymph node stage, cell membrane staining was found to have independent significance as a prognostic factor (Table lIla) but significance was lost when histological grade was included in the analysis (Table IIIb) . (Slamon et al., 1987; Venter et al., 1987) and it has been argued that this approach is the most appropriate for routine evaluation years of follow-up. We believe that identification of an effect of c-erbB-2 status in node negative patients would require a study of a larger number of patients with longer follow-up. Our series is of particular importance being the largest reported and comprising a consecutive series of patients with primary operable breast cancer presenting to and being treated by a single centre. It should end the controversy concerning the prognostic value of c-erbB-2 immunoreactivity. The findings are consistent with most other reports (Varley et al., 1987; Slamon et al., 1987; Walker et al., 1989; Tsuda et al., 1989; Wright et al., 1989; Slamon et al., 1989; Tandon et al., 1989) but less significant (Van de Vijver et al., 1988a; Barnes et al., 1988) and opposing results have been reported Gusterson et al., 1988; Ali et al., 1988; Zhou et al., 1989) . Although significant, the association shown with survival appears to be less powerful than some existing prognostic factors. The low percentage, 15-20% in most series, of invasive breast carcinoma showing gene amplification requires that large numbers of patients are studied before a significant relationship with prognosis can be demonstrated. This observation alone could explain most of the discrepancies observed between reported series. Investigation of relationships between c-erbB-2 positive membrane immunoreactivity and established prognostic factors showed no correlation, in our study, with the time dependent variables of lymph node stage and tumour size. This finding is similar to those of some groups (Van der Vijver et al., 1988a; Slamon et al., 1987; Tsuda et al., 1989; Tandon et al., 1989; Cox, 1972) but is inconsistent with others Rio et al., 1987; Berger et al., 1988; Guerin et al., 1989; Seshadri et al., 1989; Borg et al., 1989) who showed a positive correlation between c-erbB-2 oncoprotein and positive nodal status. Two groups have reported an association with tumour size (Van de Vijver et al., 1988a; Borg et al., 1989 ) but others have not Slamon et al., 1987; Tsuda et al., 1989; Wright et al., 1989; Tandon et al., 1989) . In the larger series of patients with primary operable cancer we have demonstrated a positive correlation between worsening histological grade and positive membrane immunoreactivity. A similar observation has been made by some groups (Zhou et al., 1987; Barnes et al., 1988; Berger et al., 1988; Walker et al., 1989; Wright et al., 1989; Paik et al., 1990 ) but others have not identified such a relationship (Rio et al., 1987; Van de Vijver 1988a; Guerin et al., 1989) . We failed to confirm a similar relationship with histological grade in the advanced breast cancer series. Some of these discrepancies could be explained by differences in selection criteria for patients entered into a particular study and again the low frequency of c-erbB-2 protein expression and low numbers of patients studied.
There are many recognised prognostic factors in human breast cancer. In our breast cancer series we have previously demonstrated that the most powerful factors are lymph node stage, histological grade and tumour size (Todd et al., 1987) . The multivariate analysis in this study indicates that c-erbB-2 protein expression is a significant prognostic factor only when assessed with the time related prognostic factors, tumour size and lymph node stage. When the powerful tumour related prognostic factor, histological grade, was introduced into the analysis the independent significance of c-erbB-2 protein expression was lost. c-erbB-2 amplification is found in only a small proportion of tumours and for this reason alone it is perhaps not surprising that it fails to provide prognostic information of a magnitude similar to histological grade. It is difficult to speculate on the potential value of knowledge of elevated c-erbB-2 protein expression without precise knowledge of its function (see below). Speculation that amplification and over expression of certain genes may be reflected in tumour cell morphology (Cardiff, 1988) has been partly borne out by evidence that c-erbB-2 amplification is related to large cell morphology, particularly in ductal carcinoma in situ (Van de Vijver et al., 1988b) . Histological grading is assessed by combining the appearance of various morphological features and mitotic figure frequency (Elston, 1987) . It thus provides a summation of a variety of tumour variables. Extrapolating further from the above tentative evidence, one could suggest that histological grade gives an overview of various molecular events affecting morphological appearance. It is unlikely therefore that a single molecular event could compete with histological grade in such a statistical multivariate analysis. We believe the future clinical application of molecular markers of prognosis will be in combination, providing information analogous to histological grade.
Our knowledge of the function of c-erbB-2 oncoprotein is rudimentary. It has similarities to EGFR and there is sufficient evidence to indicate that its role as a membrane receptor for a ligand, yet unknown, is likely. It is persistently overexpressed in a significant proportion of breast carcinomas and clearly delineates a poorer prognostic subgroup. Further support for c-erbB-2's growth regulatory role is the observation that monoclonal antibodies raised against the extracellular domain (Drebin et al., 1986) have exerted an antitumour effect on mutant neu transformed NIH 3T3 cells and on human breast tumour derived cell line. In addition we know that EGFR expression is associated with poorer prognosis and one might postulate that EGFR and c-erbB-2 oncoprotein are both components of a mechanism responsible for breast tumours or progression. Certainly Kadowaki et al. (1987) has demonstrated that c-erbB-2 oncoprotein can act as a substrate for EGFR tyrosine kinase. A possible hypothesis, of course, is that binding of ligand to increasing number of receptors leads to an elevation in phosphokinase activity which would promote cell replication. It has recently been demonstrated that a combination of expression of EGFR and c-erbB-2 more efficiently transforms cells than either protein alone (Kokai et al., 1989) .
In summary, our study has confirmed that c-erbB-2 overexpression is an important molecular prognostic indicator in breast carcinoma and clearly delineates a poorer prognostic subgroup. This information has clinical implications and if the ligand receptor hypothesis is correct a new chemotherapeutic dimension may be introduced once more knowledge is acquired on a molecular biological level.
